• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Vasculitis Center

Show Search
Hide Search
  • About Our Center
    • Appointments and Directions
    • Meet Our Team
    • Support Our Center
  • What is Vasculitis?
    • Types of Vasculitis
    • Causes of Vasculitis
    • Symptoms of Vasculitis
    • Diagnosing Vasculitis
  • Vasculitis Treatments
    • Prednisone
    • Avacopan (Tavneos®)
    • Apremilast (Otezla®)
    • Azathioprine
    • Colchicine
    • Cyclophosphamide (Cytoxan)
    • Dapsone
    • Supplemental Immunoglobulin (IVIG/SCIG)
    • Leflunomide
    • Mepolizumab (Nucala®)
    • Methotrexate (MTX)
    • Mycophenolate
    • Rituximab
    • Sarilumab (Kevzara®)
    • TNF Inhibitors
    • Tocilizumab (Actemra®)
  • Vasculitis Research
  • Resources
Home / Vasculitis Treatments / Apremilast (Otezla®)

Apremilast (Otezla®)

What is apremilast?

Apremilast is an oral drug used in the treatment of Behcet’s disease. Apremilast is specifically approved for the treatment of oral ulcers in Behcet’s disease, and not for other manifestations of Behcet’s.

How does apremilast work?

Apremilast blocks an enzyme called phosphodiesterase 4 which plays a role in inflammation.

How is apremilast given?

The dosing for Behcet’s disease is 30 mg by mouth twice daily. The drug is started gradually according to a standardized escalation plan to reach the final dose of 30 mg twice daily.

Side effects:

Apremilast can cause side effects including diarrhea, nausea, headache, depression, and respiratory infections.

All immunosuppressants require regular monitoring in the form of blood tests, in-person assessments, and vigilance for signs of infection.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Use of this Site

All information contained within the Johns Hopkins Vasculitis website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar


donate to the Johns Hopkins Vasculitis Center

All information contained within the Johns Hopkins Vasculitis Center website is intended for educational purposes only. Visitors are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine

© 2025 Johns Hopkins Vasculitis Center
Patient Privacy